Medigene Presents at CAR-TCR Summit Europe Showcasing Unique Approach for Development of Differentiated TCR-T Therapies

Durch | 1. März 2024

Planegg/Martinsried, February 29, 2024. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today highlighted recent updates on the progress made within key areas of its proprietary End-to-End Platform, at the 7th CAR-TCR Summit Europe taking place in London from… […]

Medigene Presents at CAR-TCR Summit Europe Showcasing Unique Approach for Development of Differentiated TCR-T Therapies
Autoren-Avatar
LabNews Media LLC
LabNews: Biotech. Digital Health. Life Sciences. Pugnalom: Environmental News. Nature Conservation. Climate Change. augenauf.blog: Wir beobachten Missstände
Autor: LabNews Media LLC

LabNews: Biotech. Digital Health. Life Sciences. Pugnalom: Environmental News. Nature Conservation. Climate Change. augenauf.blog: Wir beobachten Missstände